Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

Rhea-AI Summary

Scienture Holdings (Nasdaq: SCNX) has announced a registered direct offering of 3,225,000 shares of common stock at $1.20 per share, aiming to raise approximately $3.9 million in gross proceeds. The offering is expected to close on August 15, 2025.

The company is utilizing its effective shelf registration statement on Form S-3, with Maxim Group LLC serving as the sole placement agent. The offering will be made available through a prospectus supplement and accompanying prospectus to be filed with the SEC.

Positive

• Raising $3.9 million in additional capital to support operations
• Offering made through established shelf registration, streamlining the process

Negative

• Potential dilution for existing shareholders with 3,225,000 new shares
• Offering price of $1.20 per share may reflect current market challenges

Insights

Capital Markets Analyst

Scienture's $3.9M stock offering at $1.20/share represents significant dilution, potentially indicating cash needs amid challenging fundraising conditions.

Scienture Holdings is raising $3.9 million through a registered direct offering of 3,225,000 common shares priced at $1.20 per share. This financing mechanism, facilitated by Maxim Group as placement agent, signals potential capital constraints that warrant investor attention. The pricing reveals concerning dynamics – with the offering priced at what appears to be a discount to recent trading, suggesting weak demand or negotiating position. The timing is particularly notable as the shelf registration was declared effective just 6 days ago on August 8, indicating urgency in securing these funds. Most significantly, this represents substantial dilution for existing shareholders, increasing the outstanding share count without a clear articulated use for the proceeds. The absence of any stated purpose for these funds is a critical omission – whether for operational runway, debt servicing, acquisition opportunities, or R&D advancement would significantly impact how investors should interpret this move. While registered direct offerings provide quicker access to capital than traditional secondary offerings, they typically come with higher costs and signal potential difficulties in securing more favorable financing terms. The $3.9 million raise is relatively modest for a Nasdaq-listed pharmaceutical holding company, suggesting this may be bridge financing rather than transformative capital for major initiatives.

Commack, NY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Scienture Holdings, Inc. (Nasdaq: SCNX) (“Scienture” or the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 3,225,000 shares of common stock at an offering price of $1.20 per share, in a registered direct offering. The gross proceeds for the offering are expected to be approximately $3.9 million before deducting placement agent fees and other offering expenses. This offering is expected to close on August 15, 2025, subject to customary closing conditions.

Maxim Group LLC is acting as sole placement agent in connection with the offering.

The offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-289198), previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 1, 2025, and declared effective on August 8, 2025. The shares may be offered only by means of a prospectus. A prospectus supplement and an accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the prospectus supplement and accompanying prospectus, relating to the offering may also be obtained by contacting Maxim Group LLC, at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Prospectus Department, or by telephone at (212) 895-3745 or by email at syndicate@maximgrp.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Scienture Holdings, Inc.

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels.

For more information please visit www.scienture.com.

Forward-Looking Statements

This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch and the success those products may have in the marketplace. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “seek,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include the Company’s ability to satisfy closing conditions for the registered direct offering; risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.

Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

Contact:

SCIENTURE HOLDINGS, INC.
20 Austin Blvd.
Commack, NY 11725
Phone: (631) 670-6039
Email: IR@scienture.com

FAQ

What is the size and price of Scienture Holdings' (SCNX) August 2025 offering?

Scienture Holdings is offering 3,225,000 shares at $1.20 per share, aiming to raise $3.9 million in gross proceeds.

When will SCNX's registered direct offering close?

The offering is expected to close on August 15, 2025, subject to customary closing conditions.

Who is the placement agent for Scienture Holdings' 2025 offering?

Maxim Group LLC is acting as the sole placement agent for the offering.

How will the $3.9 million offering affect SCNX shareholders?

The offering of 3,225,000 new shares will likely result in dilution for existing shareholders, impacting their ownership percentage in the company.

What is the purpose of SCNX's registered direct offering?

While not explicitly stated, the offering will raise $3.9 million in gross proceeds, typically used to support operations, development, and distribution of specialty pharmaceutical products.